Deutsche Bank
RPRX icon

Deutsche Bank’s Royalty Pharma RPRX Stock Holding History

Deutsche Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152M Buy
2,717,951
+264,648
+11% +$13.8M 0.04% 370
2026
Q1 		$118M Buy
2,453,303
+268,224
+12% +$11.7M 0.04% 424
2025
Q4 		$84.4M Buy
2,185,079
+248,631
+13% +$9.48M 0.03% 505
2025
Q3 		$68.3M Buy
1,936,448
+185,196
+11% +$6.7M 0.02% 541
2025
Q2 		$63.1M Buy
1,751,252
+336,326
+24% +$11.1M 0.02% 551
2025
Q1 		$44M Sell
1,414,926
-1,775,038
-56% -$56.3M 0.02% 648
2024
Q4 		$81.4M Buy
3,189,964
+847,704
+36% +$22.5M 0.03% 513
2024
Q3 		$66.3M Buy
2,342,260
+1,362,476
+139% +$37.7M 0.03% 531
2024
Q2 		$25.8M Buy
979,784
+410,590
+72% +$11.4M 0.01% 742
2024
Q1 		$17.3M Buy
569,194
+12,189
+2% +$359K 0.01% 854
2023
Q4 		$15.6M Buy
557,005
+61,764
+12% +$1.7M 0.01% 856
2023
Q3 		$13.4M Sell
495,241
-350,974
-41% -$10.4M 0.01% 802
2023
Q2 		$26M Buy
846,215
+313,151
+59% +$10.6M 0.01% 690
2023
Q1 		$19.2M Sell
533,064
-75,001
-12% -$2.78M 0.01% 773
2022
Q4 		$24M Buy
608,065
+119,004
+24% +$4.97M 0.01% 712
2022
Q3 		$19.6M Buy
489,061
+31,101
+7% +$1.33M 0.01% 760
2022
Q2 		$19.3M Sell
457,960
-456
-0.1% -$18.7K 0.01% 791
2022
Q1 		$17.9M Buy
458,416
+27,320
+6% +$1.07M 0.01% 870
2021
Q4 		$17.2M Buy
431,096
+115,190
+36% +$4.48M 0.01% 902
2021
Q3 		$11.4M Buy
315,906
+71,998
+30% +$2.8M 0.01% 1099
2021
Q2 		$10M Buy
243,908
+68,124
+39% +$2.9M ﹤0.01% 1189
2021
Q1 		$7.67M Sell
175,784
-41,943
-19% -$1.99M ﹤0.01% 1324
2020
Q4 		$10.9M Buy
217,727
+215,925
+11,983% +$9.16M 0.01% 998
2020
Q3 		$76K Buy
+1,802
New +$77.3K ﹤0.01% 3671

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's RPRX Position: Q2 2026 in Review

Deutsche Bank increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $13.8M and bringing the position to 2,717,951 shares worth $152M. The position accounts for 0.04% of the portfolio, ranked #370.

Deutsche Bank first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 644 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Deutsche Bank held 2,717,951 shares of Royalty Pharma worth $152M as of Q2 2026.
  • Deutsche Bank bought 264,648 Royalty Pharma shares in Q2 2026, an estimated $13.8M.
  • Royalty Pharma made up 0.04% of Deutsche Bank's portfolio in Q2 2026, its #370 holding.
  • Deutsche Bank first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 644 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.